LLY
Eli Lilly and Company
Quarterly revenue, EPS, free cash flow, valuation, and Rule of 40 scores for Eli Lilly and Company.
Eli Lilly has become the world's most valuable pharmaceutical company, surpassing $1 trillion market cap in late 2025. The GLP-1 drugs Mounjaro and Zepbound are driving explosive growth — Q4 2025 revenue surged 43% to $19.3B, with tirzepatide sales doubling to $36.5B annually. The FDA crackdown on compounded weight-loss drugs protects Lilly's moat against competitors like Hims & Hers. With 2026 revenue guidance of $80-83B and massive manufacturing investments ($3.5B Pennsylvania facility), Lilly is all-in on the obesity revolution while diversifying into Alzheimer's (Kisunla) and oncology.
Latest Coverage
HIMS Perfect Storm: FDA, DOJ, and Novo Nordisk Close In — Stock Down 75% From Highs
Hims & Hers faces a triple regulatory and legal assault. FDA crackdown, DOJ criminal referral, and now a Novo Nordisk patent lawsuit have cratered the stock from $68 to $17 in weeks. We break down the compounding threats.
Eli Lilly Stock Rebounds After FDA Crackdown on Weight-Loss Drug Copies
Shares rose after FDA vowed action against illegal compounded versions (e.g., from Hims & Hers); protects Lilly's market for Zepbound amid pricing pressures.
Hims Launches $99 GLP-1 Pill, Undercuts Novo Nordisk by 90%
Hims debuts compounded oral semaglutide at $49-99/month vs $936+ for branded. But without Novo's patented SNAC absorption tech, critics call it a 'waste of $49.' The science and market implications.
Eli Lilly Outperforms Novo Nordisk Amid Patient Preference Shift
Analysts note lean toward Lilly's drugs like Mounjaro over rivals; Q4 results highlight market share gains despite competition from cheaper pills.
Eli Lilly Shares Boosted by GLP-1s
In-depth earnings breakdown: Q4 revenue beat at $19.3B, GLP-1 dominance (Tirzepatide sales doubled to $36.5B), pipeline updates like Orforglipron, and rotation into healthcare amid tech sell-offs.
Eli Lilly Pricing Deals and Partnerships Reset Outlook for Weight-Loss Drugs
Details landmark U.S. government deals lowering costs for Zepbound/Mounjaro under Medicare; analyzes partnerships shaking up obesity market, potential sales impacts, and competitive edge over Novo Nordisk.
Earnings release dates
Company History
Key Players
Short interest data unavailable for LLY.
